FH-5

FH-5 is a dual-target small molecule inhibitor that simultaneously targets FMS-like tyrosine kinase 3 (FLT3) and histone deacetylase 8 (HDAC8). Developed by researchers at the Affiliated Huai'an Hospital of Xuzhou Medical University, FH-5 was identified through structure-based virtual screening and has demonstrated potent anti-leukemic activity in preclinical models of acute myeloid leukemia (AML). In vitro studies show IC50 values of 0.31 nM for FLT3 and 2.91 nM for HDAC8, significantly outperforming positive controls like quinzatinib and vorinostat. In vivo, FH-5 has shown dose-dependent tumor inhibition in KG-1 cell xenograft models, achieving a 78% inhibition rate at 10 mg/kg without significant weight loss in mice, suggesting a favorable safety profile for further development.